Share Price and Basic Stock Data
Last Updated: February 3, 2026, 2:25 am
| PEG Ratio | 3.06 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
J B Chemicals & Pharmaceuticals Ltd operates in the pharmaceuticals sector, focusing on the manufacturing and marketing of a diverse range of medicines. As of September 2023, the company’s share price stood at ₹1,856, with a market capitalization of ₹29,721 Cr. The firm reported total sales of ₹3,149 Cr for the year ending March 2023, which rose to ₹3,484 Cr in March 2024 and is anticipated to reach ₹3,918 Cr by March 2025. Quarterly sales trends reflect a robust performance, with the latest reported figure for June 2025 at ₹1,094 Cr, showcasing a significant increase from ₹762 Cr in March 2023. The operating profit margin (OPM) has also shown improvement, standing at 29% for the latest fiscal year. This upward trajectory in revenues and margins suggests a strong operational framework and market positioning within the highly competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
J B Chemicals & Pharmaceuticals demonstrated commendable profitability metrics, with a reported net profit of ₹718 Cr for the trailing twelve months. The company’s return on equity (ROE) stood at 20.1%, indicating effective use of shareholder equity to generate profits. The return on capital employed (ROCE) was recorded at 25.8%, underscoring efficient capital utilization. The operating profit margins reflected consistent performance, averaging around 26% to 29% over recent quarters. The interest coverage ratio (ICR) was notably high at 91.24x, suggesting that the company is well-positioned to meet its interest obligations. However, the cash conversion cycle (CCC) of 109 days points towards potential inefficiencies in managing working capital, as lower values are typically preferred in the sector.
Balance Sheet Strength and Financial Ratios
The balance sheet of J B Chemicals & Pharmaceuticals reflects strong financial health, with total assets reported at ₹4,712 Cr as of September 2025. The company’s reserves have increased to ₹3,790 Cr, while borrowings remain minimal at ₹19 Cr, indicating a low debt level and a conservative financial strategy. The price-to-book value (P/BV) ratio stood at 7.36x, which is relatively high compared to typical sector ranges, suggesting that the market values the company highly in relation to its net assets. The current ratio of 3.04x and quick ratio of 2.20x indicate adequate liquidity to meet short-term obligations. Overall, these metrics portray a solid foundation for future growth, although the high P/BV ratio may raise questions about future valuation sustainability.
Shareholding Pattern and Investor Confidence
The shareholding structure of J B Chemicals & Pharmaceuticals indicates a diverse ownership landscape. As of September 2025, promoters held 47.56% of the shares, while foreign institutional investors (FIIs) accounted for 15.31%, and domestic institutional investors (DIIs) held 22.83%. The public ownership stood at 14.31%. This distribution reflects a moderate level of promoter control, which is declining from 53.95% in December 2022, potentially signaling a shift towards increased institutional interest. The total number of shareholders increased to 71,957, suggesting growing investor confidence in the company’s prospects. However, the decline in promoter shareholding may raise concerns about long-term commitment, even as institutional backing appears robust.
Outlook, Risks, and Final Insight
Looking ahead, J B Chemicals & Pharmaceuticals is positioned favorably for continued growth, driven by strong revenue trends and solid profitability metrics. However, risks such as market volatility, regulatory changes, and potential supply chain disruptions could impact performance. Additionally, the high P/BV ratio might indicate overvaluation concerns among investors. If the company continues to enhance operational efficiencies and maintain its profitability levels, it could solidify its market position. Conversely, failure to address working capital management may hinder sustainable growth. Overall, the company’s strong fundamentals provide a solid platform for navigating potential challenges while capitalizing on growth opportunities in the pharmaceuticals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,473 Cr. | 319 | 479/192 | 71.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,464.08 Cr | 1,084.45 | 46.05 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of J B Chemicals & Pharmaceuticals Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 809 | 793 | 762 | 896 | 882 | 845 | 862 | 1,004 | 1,001 | 963 | 949 | 1,094 | 1,085 |
| Expenses | 625 | 618 | 599 | 664 | 638 | 621 | 664 | 724 | 730 | 709 | 723 | 793 | 775 |
| Operating Profit | 185 | 175 | 164 | 232 | 244 | 223 | 198 | 280 | 271 | 255 | 226 | 301 | 310 |
| OPM % | 23% | 22% | 21% | 26% | 28% | 26% | 23% | 28% | 27% | 26% | 24% | 28% | 29% |
| Other Income | 1 | 3 | 5 | 6 | 8 | 7 | 17 | 6 | 10 | 8 | 14 | 15 | 15 |
| Interest | 8 | 8 | 14 | 12 | 10 | 12 | 9 | 6 | 2 | 3 | 1 | 1 | 1 |
| Depreciation | 28 | 28 | 32 | 31 | 32 | 34 | 41 | 41 | 42 | 42 | 46 | 43 | 44 |
| Profit before tax | 150 | 141 | 122 | 194 | 209 | 184 | 165 | 240 | 237 | 218 | 193 | 272 | 279 |
| Tax % | 26% | 25% | 28% | 27% | 28% | 27% | 23% | 26% | 26% | 25% | 25% | 25% | 26% |
| Net Profit | 111 | 106 | 88 | 142 | 151 | 134 | 126 | 177 | 175 | 162 | 146 | 202 | 208 |
| EPS in Rs | 7.18 | 6.86 | 5.66 | 9.19 | 9.72 | 8.61 | 8.13 | 11.39 | 11.24 | 10.45 | 9.36 | 12.97 | 13.27 |
Last Updated: December 30, 2025, 10:05 am
Below is a detailed analysis of the quarterly data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,085.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,094.00 Cr. (Jun 2025) to 1,085.00 Cr., marking a decrease of 9.00 Cr..
- For Expenses, as of Sep 2025, the value is 775.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 793.00 Cr. (Jun 2025) to 775.00 Cr., marking a decrease of 18.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 310.00 Cr.. The value appears strong and on an upward trend. It has increased from 301.00 Cr. (Jun 2025) to 310.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 29.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Jun 2025) to 29.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 15.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 44.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Jun 2025) to 44.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 279.00 Cr.. The value appears strong and on an upward trend. It has increased from 272.00 Cr. (Jun 2025) to 279.00 Cr., marking an increase of 7.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 208.00 Cr.. The value appears strong and on an upward trend. It has increased from 202.00 Cr. (Jun 2025) to 208.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 13.27. The value appears strong and on an upward trend. It has increased from 12.97 (Jun 2025) to 13.27, marking an increase of 0.30.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,022 | 1,144 | 1,210 | 1,344 | 1,408 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | 3,484 | 3,918 | 4,092 |
| Expenses | 874 | 964 | 1,004 | 1,112 | 1,191 | 1,337 | 1,397 | 1,482 | 1,881 | 2,454 | 2,587 | 2,886 | 3,000 |
| Operating Profit | 148 | 180 | 206 | 232 | 218 | 306 | 378 | 560 | 543 | 696 | 897 | 1,032 | 1,091 |
| OPM % | 14% | 16% | 17% | 17% | 15% | 19% | 21% | 27% | 22% | 22% | 26% | 26% | 27% |
| Other Income | -27 | 11 | 58 | 50 | 37 | 41 | 41 | 112 | 39 | 10 | 37 | 38 | 52 |
| Interest | 6 | 7 | 11 | 5 | 3 | 5 | 3 | 7 | 5 | 36 | 44 | 12 | 6 |
| Depreciation | 28 | 39 | 41 | 47 | 57 | 56 | 66 | 69 | 73 | 114 | 138 | 171 | 176 |
| Profit before tax | 87 | 146 | 212 | 230 | 194 | 287 | 349 | 597 | 505 | 555 | 752 | 887 | 962 |
| Tax % | 30% | 31% | 23% | 20% | 28% | 32% | 22% | 25% | 24% | 26% | 26% | 26% | |
| Net Profit | 62 | 100 | 163 | 184 | 139 | 194 | 272 | 449 | 386 | 410 | 553 | 660 | 718 |
| EPS in Rs | 3.63 | 5.92 | 9.58 | 10.85 | 8.28 | 12.05 | 17.60 | 28.98 | 24.93 | 26.48 | 35.61 | 42.37 | 46.05 |
| Dividend Payout % | 41% | 118% | 26% | 5% | 12% | 21% | 31% | 28% | 33% | 34% | 34% | 37% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 61.29% | 63.00% | 12.88% | -24.46% | 39.57% | 40.21% | 65.07% | -14.03% | 6.22% | 34.88% | 19.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -50.12% | -37.34% | 64.02% | 0.64% | 24.87% | -79.10% | 20.25% | 28.66% | -15.53% |
J B Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 20% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 34% |
| 3 Years: | 23% |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 20% |
| 3 Years: | 19% |
| Last Year: | 20% |
Last Updated: September 5, 2025, 8:10 am
Balance Sheet
Last Updated: December 4, 2025, 1:28 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 | 16 |
| Reserves | 1,026 | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,908 | 3,418 | 3,790 |
| Borrowings | 93 | 127 | 193 | 49 | 29 | 26 | 29 | 45 | 55 | 572 | 378 | 28 | 19 |
| Other Liabilities | 215 | 365 | 270 | 262 | 294 | 286 | 349 | 376 | 412 | 495 | 687 | 804 | 887 |
| Total Liabilities | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,265 | 4,712 |
| Fixed Assets | 311 | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 2,004 | 1,968 | 1,977 |
| CWIP | 46 | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 63 | 32 |
| Investments | 500 | 552 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 | 345 | 519 |
| Other Assets | 494 | 552 | 594 | 580 | 674 | 699 | 743 | 894 | 1,293 | 1,385 | 1,519 | 1,889 | 2,184 |
| Total Assets | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,265 | 4,712 |
Below is a detailed analysis of the balance sheet data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,790.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,418.00 Cr. (Mar 2025) to 3,790.00 Cr., marking an increase of 372.00 Cr..
- For Borrowings, as of Sep 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 28.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 887.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 804.00 Cr. (Mar 2025) to 887.00 Cr., marking an increase of 83.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,712.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,265.00 Cr. (Mar 2025) to 4,712.00 Cr., marking an increase of 447.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,977.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,968.00 Cr. (Mar 2025) to 1,977.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Sep 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Mar 2025) to 32.00 Cr., marking a decrease of 31.00 Cr..
- For Investments, as of Sep 2025, the value is 519.00 Cr.. The value appears strong and on an upward trend. It has increased from 345.00 Cr. (Mar 2025) to 519.00 Cr., marking an increase of 174.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,184.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,889.00 Cr. (Mar 2025) to 2,184.00 Cr., marking an increase of 295.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,712.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,265.00 Cr. (Mar 2025) to 4,712.00 Cr., marking an increase of 447.00 Cr..
Notably, the Reserves (3,790.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 55.00 | 53.00 | 13.00 | 183.00 | 189.00 | 280.00 | 349.00 | 515.00 | 488.00 | 124.00 | 519.00 | -27.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 84 | 84 | 82 | 72 | 78 | 68 | 71 | 70 | 84 | 67 | 72 | 76 |
| Inventory Days | 120 | 122 | 146 | 138 | 145 | 149 | 159 | 181 | 178 | 134 | 155 | 147 |
| Days Payable | 54 | 63 | 71 | 68 | 75 | 72 | 97 | 97 | 97 | 75 | 110 | 114 |
| Cash Conversion Cycle | 150 | 143 | 158 | 142 | 148 | 146 | 133 | 153 | 164 | 127 | 117 | 109 |
| Working Capital Days | 70 | 16 | 38 | 75 | 93 | 91 | 81 | 91 | 122 | 81 | 55 | 79 |
| ROCE % | 13% | 13% | 15% | 14% | 11% | 18% | 23% | 33% | 23% | 22% | 25% | 26% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Kotak Midcap Fund | 4,816,878 | 1.45 | 876.53 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,984,782 | 2.05 | 543.14 | 2,207,475 | 2025-12-08 05:55:37 | 35.21% |
| Franklin India Small Cap Fund | 1,448,723 | 1.99 | 263.62 | N/A | N/A | N/A |
| Canara Robeco Small Cap Fund | 1,353,805 | 1.88 | 246.35 | 790,068 | 2025-12-08 05:55:37 | 71.35% |
| Axis ELSS Tax Saver Fund | 1,087,630 | 0.58 | 197.92 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 999,649 | 2.2 | 181.91 | 1,486,868 | 2025-12-08 04:19:42 | -32.77% |
| Nippon India Small Cap Fund | 991,107 | 0.26 | 180.35 | 937,872 | 2025-12-08 05:55:37 | 5.68% |
| Axis Midcap Fund | 984,875 | 0.57 | 179.22 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 898,827 | 0.32 | 163.56 | 949,834 | 2025-12-15 04:02:53 | -5.37% |
| Kotak Small Cap Fund | 776,804 | 0.82 | 141.36 | 1,296,204 | 2026-01-25 13:22:10 | -40.07% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 42.45 | 35.66 | 53.00 | 49.86 | 57.96 |
| Diluted EPS (Rs.) | 41.56 | 34.85 | 52.34 | 49.86 | 57.96 |
| Cash EPS (Rs.) | 53.36 | 44.52 | 67.77 | 59.35 | 66.92 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 220.54 | 188.36 | 320.55 | 276.73 | 234.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 220.54 | 188.36 | 320.55 | 276.73 | 234.65 |
| Revenue From Operations / Share (Rs.) | 251.67 | 224.50 | 407.00 | 313.69 | 264.29 |
| PBDIT / Share (Rs.) | 68.74 | 60.19 | 91.20 | 75.40 | 87.06 |
| PBIT / Share (Rs.) | 57.76 | 51.28 | 76.42 | 66.00 | 78.17 |
| PBT / Share (Rs.) | 57.00 | 48.42 | 71.76 | 65.33 | 77.23 |
| Net Profit / Share (Rs.) | 42.37 | 35.61 | 52.99 | 49.95 | 58.04 |
| NP After MI And SOA / Share (Rs.) | 42.37 | 35.61 | 52.97 | 49.86 | 57.96 |
| PBDIT Margin (%) | 27.31 | 26.81 | 22.40 | 24.03 | 32.93 |
| PBIT Margin (%) | 22.94 | 22.84 | 18.77 | 21.03 | 29.57 |
| PBT Margin (%) | 22.64 | 21.56 | 17.63 | 20.82 | 29.22 |
| Net Profit Margin (%) | 16.83 | 15.86 | 13.01 | 15.92 | 21.95 |
| NP After MI And SOA Margin (%) | 16.83 | 15.86 | 13.01 | 15.89 | 21.93 |
| Return on Networth / Equity (%) | 19.21 | 18.90 | 16.52 | 18.05 | 24.75 |
| Return on Capital Employeed (%) | 24.69 | 25.45 | 19.71 | 22.93 | 31.91 |
| Return On Assets (%) | 15.43 | 13.83 | 11.53 | 14.77 | 20.01 |
| Long Term Debt / Equity (X) | 0.00 | 0.01 | 0.15 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.12 | 0.22 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 0.94 | 0.92 | 1.02 | 0.91 | 0.94 |
| Current Ratio (X) | 3.04 | 2.13 | 2.76 | 3.32 | 4.50 |
| Quick Ratio (X) | 2.20 | 1.56 | 1.98 | 2.25 | 3.49 |
| Inventory Turnover Ratio (X) | 7.60 | 1.75 | 1.87 | 1.73 | 1.96 |
| Dividend Payout Ratio (NP) (%) | 35.93 | 28.40 | 31.13 | 33.09 | 16.38 |
| Dividend Payout Ratio (CP) (%) | 28.53 | 22.72 | 24.33 | 27.84 | 14.21 |
| Earning Retention Ratio (%) | 64.07 | 71.60 | 68.87 | 66.91 | 83.62 |
| Cash Earning Retention Ratio (%) | 71.47 | 77.28 | 75.67 | 72.16 | 85.79 |
| Interest Coverage Ratio (X) | 91.24 | 21.07 | 19.57 | 113.79 | 92.91 |
| Interest Coverage Ratio (Post Tax) (X) | 57.24 | 13.47 | 12.37 | 76.39 | 62.94 |
| Enterprise Value (Cr.) | 25138.28 | 25860.24 | 15719.76 | 12145.74 | 9693.57 |
| EV / Net Operating Revenue (X) | 6.42 | 7.42 | 4.99 | 5.01 | 4.75 |
| EV / EBITDA (X) | 23.49 | 27.68 | 22.28 | 20.84 | 14.41 |
| MarketCap / Net Operating Revenue (X) | 6.45 | 7.35 | 4.84 | 5.02 | 4.74 |
| Retention Ratios (%) | 64.06 | 71.59 | 68.86 | 66.90 | 83.61 |
| Price / BV (X) | 7.36 | 8.76 | 6.15 | 5.70 | 5.35 |
| Price / Net Operating Revenue (X) | 6.45 | 7.35 | 4.84 | 5.02 | 4.74 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 |
After reviewing the key financial ratios for J B Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 42.45. This value is within the healthy range. It has increased from 35.66 (Mar 24) to 42.45, marking an increase of 6.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 41.56. This value is within the healthy range. It has increased from 34.85 (Mar 24) to 41.56, marking an increase of 6.71.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.36. This value is within the healthy range. It has increased from 44.52 (Mar 24) to 53.36, marking an increase of 8.84.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 220.54. It has increased from 188.36 (Mar 24) to 220.54, marking an increase of 32.18.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 220.54. It has increased from 188.36 (Mar 24) to 220.54, marking an increase of 32.18.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 251.67. It has increased from 224.50 (Mar 24) to 251.67, marking an increase of 27.17.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 68.74. This value is within the healthy range. It has increased from 60.19 (Mar 24) to 68.74, marking an increase of 8.55.
- For PBIT / Share (Rs.), as of Mar 25, the value is 57.76. This value is within the healthy range. It has increased from 51.28 (Mar 24) to 57.76, marking an increase of 6.48.
- For PBT / Share (Rs.), as of Mar 25, the value is 57.00. This value is within the healthy range. It has increased from 48.42 (Mar 24) to 57.00, marking an increase of 8.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 42.37. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 42.37, marking an increase of 6.76.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.37. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 42.37, marking an increase of 6.76.
- For PBDIT Margin (%), as of Mar 25, the value is 27.31. This value is within the healthy range. It has increased from 26.81 (Mar 24) to 27.31, marking an increase of 0.50.
- For PBIT Margin (%), as of Mar 25, the value is 22.94. This value exceeds the healthy maximum of 20. It has increased from 22.84 (Mar 24) to 22.94, marking an increase of 0.10.
- For PBT Margin (%), as of Mar 25, the value is 22.64. This value is within the healthy range. It has increased from 21.56 (Mar 24) to 22.64, marking an increase of 1.08.
- For Net Profit Margin (%), as of Mar 25, the value is 16.83. This value exceeds the healthy maximum of 10. It has increased from 15.86 (Mar 24) to 16.83, marking an increase of 0.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.83. This value is within the healthy range. It has increased from 15.86 (Mar 24) to 16.83, marking an increase of 0.97.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.21. This value is within the healthy range. It has increased from 18.90 (Mar 24) to 19.21, marking an increase of 0.31.
- For Return on Capital Employeed (%), as of Mar 25, the value is 24.69. This value is within the healthy range. It has decreased from 25.45 (Mar 24) to 24.69, marking a decrease of 0.76.
- For Return On Assets (%), as of Mar 25, the value is 15.43. This value is within the healthy range. It has increased from 13.83 (Mar 24) to 15.43, marking an increase of 1.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.12 (Mar 24) to 0.00, marking a decrease of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has increased from 0.92 (Mar 24) to 0.94, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.04, marking an increase of 0.91.
- For Quick Ratio (X), as of Mar 25, the value is 2.20. This value exceeds the healthy maximum of 2. It has increased from 1.56 (Mar 24) to 2.20, marking an increase of 0.64.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 7.60, marking an increase of 5.85.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 35.93. This value is within the healthy range. It has increased from 28.40 (Mar 24) to 35.93, marking an increase of 7.53.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from 22.72 (Mar 24) to 28.53, marking an increase of 5.81.
- For Earning Retention Ratio (%), as of Mar 25, the value is 64.07. This value is within the healthy range. It has decreased from 71.60 (Mar 24) to 64.07, marking a decrease of 7.53.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 71.47. This value exceeds the healthy maximum of 70. It has decreased from 77.28 (Mar 24) to 71.47, marking a decrease of 5.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 91.24. This value is within the healthy range. It has increased from 21.07 (Mar 24) to 91.24, marking an increase of 70.17.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 57.24. This value is within the healthy range. It has increased from 13.47 (Mar 24) to 57.24, marking an increase of 43.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25,138.28. It has decreased from 25,860.24 (Mar 24) to 25,138.28, marking a decrease of 721.96.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.42. This value exceeds the healthy maximum of 3. It has decreased from 7.42 (Mar 24) to 6.42, marking a decrease of 1.00.
- For EV / EBITDA (X), as of Mar 25, the value is 23.49. This value exceeds the healthy maximum of 15. It has decreased from 27.68 (Mar 24) to 23.49, marking a decrease of 4.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.45. This value exceeds the healthy maximum of 3. It has decreased from 7.35 (Mar 24) to 6.45, marking a decrease of 0.90.
- For Retention Ratios (%), as of Mar 25, the value is 64.06. This value is within the healthy range. It has decreased from 71.59 (Mar 24) to 64.06, marking a decrease of 7.53.
- For Price / BV (X), as of Mar 25, the value is 7.36. This value exceeds the healthy maximum of 3. It has decreased from 8.76 (Mar 24) to 7.36, marking a decrease of 1.40.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.45. This value exceeds the healthy maximum of 3. It has decreased from 7.35 (Mar 24) to 6.45, marking a decrease of 0.90.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in J B Chemicals & Pharmaceuticals Ltd:
- Net Profit Margin: 16.83%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.69% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.21% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 57.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.2
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 40 (Industry average Stock P/E: 46.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.83%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Neelam Centre, 'B' Wing, 4th floor, Mumbai Maharashtra 400030 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Duggal | Chairman & Ind.Director |
| Mr. Nikhil Chopra | WholeTime Director & CEO |
| Mr. Prashant Kumar | Non Executive Director |
| Mr. Gaurav Trehan | Non Executive Director |
| Mr. Akshay Tanna | Non Executive Director |
| Mr. Sumit Bose | Independent Director |
| Ms. Padmini Khare Kaicker | Independent Director |
| Mr. Ashwani Kumar Puri | Independent Director |
FAQ
What is the intrinsic value of J B Chemicals & Pharmaceuticals Ltd?
J B Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 03 February 2026) is ₹1781.74 which is 4.46% lower the current market price of ₹1,865.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹30,119 Cr. market cap, FY2025-2026 high/low of ₹1,939/1,303, reserves of ₹3,790 Cr, and liabilities of ₹4,712 Cr.
What is the Market Cap of J B Chemicals & Pharmaceuticals Ltd?
The Market Cap of J B Chemicals & Pharmaceuticals Ltd is 30,119 Cr..
What is the current Stock Price of J B Chemicals & Pharmaceuticals Ltd as on 03 February 2026?
The current stock price of J B Chemicals & Pharmaceuticals Ltd as on 03 February 2026 is ₹1,865.
What is the High / Low of J B Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of J B Chemicals & Pharmaceuticals Ltd stocks is ₹1,939/1,303.
What is the Stock P/E of J B Chemicals & Pharmaceuticals Ltd?
The Stock P/E of J B Chemicals & Pharmaceuticals Ltd is 40.0.
What is the Book Value of J B Chemicals & Pharmaceuticals Ltd?
The Book Value of J B Chemicals & Pharmaceuticals Ltd is 243.
What is the Dividend Yield of J B Chemicals & Pharmaceuticals Ltd?
The Dividend Yield of J B Chemicals & Pharmaceuticals Ltd is 0.83 %.
What is the ROCE of J B Chemicals & Pharmaceuticals Ltd?
The ROCE of J B Chemicals & Pharmaceuticals Ltd is 25.8 %.
What is the ROE of J B Chemicals & Pharmaceuticals Ltd?
The ROE of J B Chemicals & Pharmaceuticals Ltd is 20.1 %.
What is the Face Value of J B Chemicals & Pharmaceuticals Ltd?
The Face Value of J B Chemicals & Pharmaceuticals Ltd is 1.00.